Silver Book Fact

A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.

Parkinson Study Group. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. Arch Neurol. 2005; 62(2): 241-8. http://archneur.ama-assn.org/cgi/content/full/62/2/241

Reference

Title
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Publication
Arch Neurol
Publication Date
2005
Authors
Parkinson Study Group
Volume & Issue
Volume 62, Issue 2
Pages
241-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
  • A $1 billion-investment in Alzheimer’s research that led to research breakthroughs by 2010 could have a 10-to-1 return by 2015, and a 90-to-1 return by 2050.  
  • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…  
  • A treatment breakthrough that slowed the progression of Alzheimer’s disease would reduce the number of people with the disease from 2.4 million to 1.1 million in 2020, and from 6.5…